Introduction
Molecular analyses of the rearranged immunoglobulin heavy chain gene variable region (VH gene) of normal and neoplastic B cells have been extensively studied to date and can provide information on the type of cell the tumor originates from. [1] [2] [3] [4] [5] [6] The degree of somatic mutation found in VH genes from normal B cells depends on their level of differentiation during the immune response. Somatic mutation rates in various B cell neoplasms often correspond to those of their normal cellular counterparts. 5, 6 For example, the rearranged VH genes of B cell neoplasms derived from pregerminal center (GC) B cells such as mantle cell lymphoma (MCL) exhibit sequences with little or no somatic mutation. Those of B cell neoplasms derived from GC B cells and post GC B cells, such as follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma, are somatically mutated. [6] [7] [8] However, B cell chronic lymphocytic leukemia (B-CLL) appears to be exceptional. The rearranged VH genes of CD5 + B-CLL are not always uniform. 8, 9 Some cases show a germline sequence of the rearranged VH gene, others show a hypermutated VH gene.
There have been three reports on somatic mutation analyses of CD5 + DLBCL. The first suggested that all cases of CD5 + DLBCL are somatically mutated. 10 The distribution of replacement and silent mutations in the VH gene of de novo CD5 + DLBCL is consistent with a pattern resulting from antigen selection, suggesting that the cell of origin is a somewhat dif- 
Materials and methods

Ten cases of de novo CD5
+ DLBCL established according to REAL and WHO classification 16 were selected from the patient files of malignant lymphoma in our department. All cases of CD5 + DLBCL consisted of mainly centroblastic lymphoma cells. No case expressed cyclin D1 and no case had a pre-existing B-CLL. Twenty-nine cases of CD5 − DLBCL with centroblastic morphology were selected for comparison. Monoclonal antibody CD5 (Novocastra Laboratories, Newcastle upon Tyne, UK) was used for the paraffin-embedded section to determine CD5 positivity. The CD5 + DLBCLs were composed of three cases of nodal presentation and seven cases of extranodal presentation, the latter being two cases in skin, one case in mediastinum and four cases in bone marrow (with or without hepatosplenomegaly). The CD5 − DLBCLs consisted of: 18 cases of nodal presentation and 11 cases of extra-nodal presentation, the latter being: one case in Waldeyer's ring, two cases in skin, two cases in breast, one case in eyelid, two cases in stomach, one case in colon and two cases in testis. No cases with high-grade transformation of lowgrade lymphoma of mucosa associated lymphoid tissue (MALT) were included.
Resected tissue was fixed in 20% buffered formalin and embedded in paraffin or snap-frozen in OCT compound (Miles, Elkhart, IN, USA) for routine histologic and immunohistochemical studies. DNA was extracted from this paraffin embedded or frozen materials. The variable region (CDR1, FW2, CDR2 and FW3) and VDJ region (CDR3) of the rearranged immunoglobulin heavy chain gene were amplified by semi-nested PCR, using primers FR1C or FR2A as the sense primer and together with anti-sense primers LJH (for first round amplification) and VLJH (for second round amplification) as previously described. [17] [18] [19] Primers were as follows: consensus V region primers:
GG-3′; consensus J region primers, LJH, 5′-TGAGGAGACGGTGACC-3′, and VLJH, 5′-GTGACCAGGGT[A/C/G/T]CCTTGGCCCC AG-3′. Intraclonal iversity was examined as previously described.
12 PCR products were ligated into the pCR R 2.1 vector and transformed into TOP10F′ cells according to the instruction manual (original A cloning kit, Invitrogen, Carlsbad, CA, USA). The colony direct PCR assay was examined hether colonies included correct PCR product. Ten and more white colonies were picked up nd put into 50 l of Insert Check ready (Toyobo, Osaka, Japan). PCR condition consisted of 30 cycles of 95°C for 20 s, 60°C for 5 s and 72°C for 30 s. Then, 10 samples including correct PCR products confirmed by check-electrophoresis for each case were sequenced by the same method as described above.
Results
De novo CD5
+ and CD5 − DLBCLs with a complete nucleotide sequence of VH gene were analyzed. Table 1 shows numbers of mutations and total nucleotides, mutation frequencies (%) and VH gene family usage. The data of VH gene of CD5 + DLBCLs (767, 95051, 97011, 97026, c347, c352 and c364) have been previously published.
12 Figure 1 shows the distribution of somatic mutation-frequency in CD5
+ and CD5 − DLBCL. All cases showed in-frame sequence. The somatic mutation frequencies in CD5 + and CD5 − DLBCL were 0.7 to 12.9% with an average of 6.2% and 2. 0 to 25.9% with an average of 11.1%, respectively. The average ratios of replacement mutations to silent mutations (R/S) for CD5 + DLBCL and de novo CD5 − DLBCL exhibited 2.00 and 2.24 (CDR2) and 1.46 and 1.45 (FW3), respectively. VH gene family usage in CD5 + DLBCL consisted of VH3; three nodal presentation and three extra-nodal presentation, and VH4; four extra-nodal presentation. In CD5 − DLBCL, it consisted of VH3; nine nodal presentation and six extra-nodal presentation and VH4; eight nodal presentation and four extra-nodal presentation.
Intraclonal diversity was analyzed in four cases of CD5
+
Figure 1
Distribution of somatic mutation frequencies of CD5 + and CD5 − diffuse large B cell lymphoma. Ten cases of CD5 + DLBCL (left) and 29 cases of CD5 − DLBCL (right) are rearranged by somatic mutation frequencies (%), respectively.
Leukemia DLBCL and seven cases of CD5 − DLBCL. Table 2 shows the nucleotide sequence of 10 cloned PCR products from CD5 + DLBCL case (C440) and 10 from CD5 − DLBCL case (96085). Further single nucleotide substitutions in unmutated nucleotide were identified, and the intraclonal diversity, which is termed the ongoing mutation rate in this study, was estimated by dividing the number of these substitutions by the total number of nucleotides analyzed. For example, in case 96085, four single nucleotide substitutions were found and the ongoing mutation rate was 0.272% (four further substitutions/147 nucleotides × 10 clones). Results for each patient are summarized in Table 1 . The average ongoing mutation rates of CD5 + and CD5
− DLBCL were 0.051% and 0.197%, respectively. These were significantly distinct (P = 0.024, t-test).
Discussion
We previously reported that both CD5 + B-CLL and CD5
+ DLBCL include some cases with germline or low frequency of somatic mutation of the rearranged VH genes, and other cases with somatically hypermutated VH genes, up to 15% of nucleotides mutated. 12 The distributions and averages rates of somatic mutation in CD5
+ B-CLL and CD5 + DLBCL were therefore quite similar. These data suggest that CD5
+ DLBCL is derived from the B1 subset of B cells (CD5 − DLBCL is not excluded, because CD5 expression may be induced in CD5 − cells during activation. 20 Matolcsy et al 21 reported that 44% cases of de novo CD5 + DLBCL exhibit bcl-6 rearrangement, so that CD5 + DLBCL and Richter's syndrome-associated DLBCL are genotypically distinct. 21 We, therefore, analyzed nucleotide sequence and intraclonal diversity of the rearranged VH gene of CD5 + and CD5 − DLBCL in order to clarify the cell origin of CD5 + DLBCL. The average somatic mutation in the 39 cases (9.8%, range: 0.7 to 25.9%) was similar to those observed by Hsu and Levy (9.9%, range: 2 to 26%) 22 and Kuppers et al 23 (8.5% , range: 4 to 22%). In our series, there was a difference between CD5 + DLBCL (0.7 to 12.9%, average 6.2%) and CD5 − DLBCL (2.0 to 25.9%, average 11.1%), and the distribution of somatic (Figure 1 ). Whereas both of nodal and bone marrow CD5 + DLBCLs showed low frequencies of mutations, extranodal CD5 + DLBCLs showed relatively high frequencies of mutations. There might be a difference in characteristics of CD5 + DLBCL between lymph node/bone marrow cases and extranodal cases. It is reported that the B-CLL cases could be divided into two groups; cases with unmutated VH genes and cases with mutated VH genes. B-CLLs with unmutated VH genes displayed higher percentages of CD38 + than those with mutated V genes, and have a more aggressive form. 24, 25 We have no available data about CD38 expression on CD5 + DLBCL at the present. Further analysis for subtyping of CD5 + DLBCL will be needed. Four cases of CD5
+ DLBCL exhibited bone marrow presentation with/without hepatosplenomegaly. There were no cases archiving a leukemic change. Two cases showed an intrasinusoidal proliferation pattern, suggesting intravascular lymphoma. Ongoing mutation (intraclonal microheterogeneity) is linked to the germinal center (GC) microenvironment in normal immune reaction. 5 It is reported that FL has an intraclonal microheterogeneity resulting from the ongoing mutation which occurs in the neoplastic lesion, because FL tends to display a similar architecture to the normal reactive follicle. [26] [27] [28] However, it remains unclear whether B cell lymphomas with a diffuse architecture show intraclonal microheterogeneity. MCL, B-CLL, Burkitt's lymphoma, splenic lymphoma with villous lymphocytes and multiple myeloma have been reported to show no intraclonal microheterogeneity. 17, 29, 30 In contrast, Table 2 Cloning assay of the VH gene of CD5
1st line, the closest germline; 2nd line, patient's consensus sequence; 3rd-12th lines, each of 10 clone's sequence.
Leukemia some B cell lymphomas have been subsequently reported to exhibit an intraclonal microheterogeneity. Intraclonal microheterogeneity is found in DLBCL, MALT lymphoma, splenic marginal zone B cell lymphoma, hepatitis C viruspositive immunocytoma and Burkitt's lymphoma, as well as Follicular lymphoma. 23, [31] [32] [33] [34] [35] In MALT lymphoma and marginal zone B cell lymphoma, the lymphoma cells occasionally re-circulate to reactive GCs, a process termed follicular colonization, and may show intraclonal microheterogeneity. 36, 37 We have examined the presence of intraclonal microheterogeneity by a subcloning assay for comparison between CD5 + and CD5
− DLBCL. The rates in CD5 + DLBCL were significantly lower than in CD5 − DLBCL. It is believed that the neoplastic cells of DLBCL are derived from GC B cells or post-GC B cell (memory B cells), which have undergone antigen selection via the GC. [2] [3] [4] [5] [6] These data may indicate that the neoplastic cells of CD5 − DLBCL may remain capable for further mutation. On the other hand, CD5
+ DLBCL, even with somatically hypermutated VH gene, exhibited no or little further mutation (very low number of the ongoing mutation rate), indicating that CD5 + DLBCL may have a different origin. It is unlikely that the normal counterparts of CD5 + DLBCL are situated in the GC where B cells undergo antigen-driven selection during B cell differentiation. We speculate that CD5 + B cell neoplasms may be derived from CD5 + B cells, which have little somatic mutation activity and may therefore undergo maturation in a different pathway. Recent reports indicate a small number of CD5 + B cells in peripheral blood with a somatically mutated VH gene, 38 supporting the presence of another pathway. CD5
+ DLBCL may help to clarify the ontogeny and differentiation of CD5 + B cells. In conclusion, we analyzed nucleotide sequence and intraclonal diversity of rearranged VH gene of de novo CD5 + and de novo CD5 − DLBCL. Distribution and average of somatic mutation frequency and the average of the ongoing mutation rate of CD5 + DLBCL and CD5 − DLBCL were significantly different. These data may indicate that the cell origin of CD5 + DLBCL is different from that of CD5 − DLBCL and may therefore be derived from the B1 subset. CD5 is not an activated antigen in DLBCL.
